Neurexis Therapeutics was formed in early 2020 to develop new medication for the prevention of brain damage following ischemic events such as stroke. Licensed from the University of Colorado Anschutz Medical Campus, this drug has the potential to significantly improve clinical outcomes for stroke and cardiac arrest patients, reduce total healthcare costs, and addresses a multibillion-dollar market opportunity.
Location: United States, Colorado, Aurora
Employees: 1-10
Total raised: $3M
Investors 1
| Date | Name | Website |
| - | VIC Techno... | victech.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.09.2024 | - | $3M | National I... |
Mentions in press and media 5
| Date | Title | Description |
| 20.09.2024 | Neurexis Therapeutics: A $3 Million Leap Towards Neuroprotection | In the heart of Aurora, Colorado, a biopharmaceutical company is poised to change the landscape of neuroprotection. Neurexis Therapeutics has secured a $3 million grant from the National Institutes of Health (NIH). This funding, part of the... |
| 18.09.2024 | Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia | Neurexis Therapeutics A promising approach for preventing cognitive and behavioral impairment following ischemia AURORA, Colo., Sept. 18, 2024 /PRNewswire-PRWeb/ -- Neurexis Therapeutics, a leading biopharmaceutical company focused on devel... |
| 18.09.2024 | Neurexis Therapeutics Secures $3M NIH Grant | Neurexis Therapeutics, an Aurora, CO-based biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of... |
| 19.04.2023 | Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN) | "This is especially critical given the lack of an FDA-approved neuroprotective drug to address the devastating impacts that stroke can have on patients.” said Dr. Olivia Asfaha, Co-Principal Investigator on the grant. AURORA, Colo. (PR... |
| 14.10.2021 | Neurexis Therapeutics Awarded NIH Phase I SBIR Grant to Accelerate IND-Enabling Studies of Neuroprotective Therapeutic | “We are encouraged by the support provided by NIH to move this promising, transformative product towards the clinic,” said Dr. Michael Artinger, CEO of Neurexis Therapeutics AURORA, Colo. (PRWEB) October 14, 2021 Neurexis Therapeutics, Inco... |